A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Public ClinicalTrials.gov record NCT03460977. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment. Part 3, which is open for enrollment is seeking men who: * have Castration Resistant Prostate Cancer (CRPC) and * have previously received treatment for CRPC and have progressed from the last treatment All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort). In the assessment phase: * participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods. * participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule. * participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule. After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding. The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Study identification
- NCT ID
- NCT03460977
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 453 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2018
- Primary completion
- Apr 19, 2028
- Completion
- Jul 6, 2029
- Last update posted
- Aug 23, 2026
2018 – 2029
United States locations
- U.S. sites
- 44
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner-University Medical Center Tucson | Tucson | Arizona | 85719 | Active, not recruiting |
| The University of Arizona Cancer Center-North Campus | Tucson | Arizona | 85719 | Active, not recruiting |
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | Active, not recruiting |
| Arizona Urology Specialists, PLLC | Tucson | Arizona | 85741 | Terminated |
| Pacific Cancer Medical Center INC | Anaheim | California | 92801 | Active, not recruiting |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | Active, not recruiting |
| City of Hope Investigational Drug Services (IDS) | Duarte | California | 91010 | Active, not recruiting |
| Norwalk Hospital | Norwalk | Connecticut | 06856 | Active, not recruiting |
| The University of Kansas Cancer Center, Investigational Drug Services | Fairway | Kansas | 66205 | Active, not recruiting |
| The University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | Active, not recruiting |
| The University of Kansas Hospital | Kansas City | Kansas | 66160 | Active, not recruiting |
| The University of Kansas Medical Center Medical Office Building | Kansas City | Kansas | 66160 | Active, not recruiting |
| The University of Kansas Cancer Center - Indian Creek Campus | Overland Park | Kansas | 66211 | Active, not recruiting |
| The University of Kansas Cancer Center | Westwood | Kansas | 66205 | Active, not recruiting |
| Norton Cancer Institute - Downtown | Louisville | Kentucky | 40202 | Active, not recruiting |
| Norton Cancer Institute, Norton Healthcare Pavilion | Louisville | Kentucky | 40202 | Active, not recruiting |
| Norton Hospital | Louisville | Kentucky | 40202 | Active, not recruiting |
| Maryland Oncology Hematology, P.A. | Rockville | Maryland | 20850 | Terminated |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Active, not recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Active, not recruiting |
| Dana Farber Cancer Institute- Chestnut Hill | Newton | Massachusetts | 02459 | Active, not recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | Recruiting |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Active, not recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Active, not recruiting |
| OU Health University of Oklahoma Medical Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Stephenson Cancer Center (chemo location) | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | Recruiting |
| Parkway Surgery Center | Myrtle Beach | South Carolina | 29572 | Recruiting |
| Sarah Cannon Research Institute - Pharmacy | Nashville | Tennessee | 37203 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Austin Midtown | Austin | Texas | 78705 | Terminated |
| University of Texas Southwestern Medical Center - Simmons Cancer Center | Dallas | Texas | 75390 | Active, not recruiting |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | Active, not recruiting |
| UT Southwestern University Hospital - William P. Clements, Jr | Dallas | Texas | 75390 | Active, not recruiting |
| UT Southwestern University Hospital - Zale Lipshy | Dallas | Texas | 75390 | Active, not recruiting |
| NEXT Dallas | Irving | Texas | 75039 | Recruiting |
| US Oncology Investigational Product Center (IPC) | Irving | Texas | 75063 | Terminated |
| US Oncology Investigational Products Center | Irving | Texas | 75063 | Terminated |
| NEXT Oncology | San Antonio | Texas | 78229 | Recruiting |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | Active, not recruiting |
| Olympic Medical Center | Port Angeles | Washington | 98362 | Active, not recruiting |
| Fred Hutchinson Cancer Center Alliance Peninsula | Poulsbo | Washington | 98370 | Active, not recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Active, not recruiting |
| University of Washington Medical Center | Seattle | Washington | 98109 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03460977, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03460977 live on ClinicalTrials.gov.